Lomitapide

83 interactions 8 explained in plain English
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Letermovir Injection Lenacapavir Injection Ketoconazole Topical Lefamulin Lenacapavir Oral Olutasidenib
5 Contraindicated 58 Major 20 Moderate
All (83) Contraindicated (5) Major (58) Moderate (20)

Major

Lomitapide Istradefylline Nourianz Increased lomitapide exposure Details Lomitapide Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Lomitapide Levonorgestrel After banger Increased lomitapide exposure Details Lomitapide Levonorgestrel Intrauterine System Kyleena Increased lomitapide exposure Details Lomitapide Linagliptin Tradjenta Increased lomitapide exposure and an increased P-gp substrate exposure Details Lomitapide Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Lomitapide Lovastatin Altocor® Increased lovastatin exposure and an increased risk of myopathy and/or rhabdomyolysis Details Lomitapide Lumateperone Caplyta Increased lomitapide exposure Details Lomitapide Lurasidone Latuda Increased lomitapide exposure Details Lomitapide Meloxicam Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Lomitapide Meloxicam Injection Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Lomitapide Methylergonovine Methergine Increased methylergonovine exposure Details Lomitapide Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Lomitapide Nifedipine Adalat® Increased NIFEdipine exposure Details Lomitapide Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Lomitapide Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Lomitapide Olaparib Lynparza Increased lomitapide exposure Details Lomitapide Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.